Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The FDA is beginning rulemaking to close the “adequate provision” loophole
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
Subscribe To Our Newsletter & Stay Updated